Brief: Biotricity Received Communication From FDA Stating Bioflux Software Device is in Substantiative Phase
21/05/2020 01:19
May 20 (Reuters) - Biotricity Inc BTCY.PK :
* BIOTRICITY FDA SUBMISSION UPDATE
* RECEIVED COMMUNICATION FROM FDA STATING BIOFLUX SOFTWARE
DEVICE
IS NOW IN SUBSTANTIATIVE PHASE OF REVIEW PROCESS
* EXPECTS FDA RESPONSE BY END OF JUNE
Source text for Eikon: ID:nGNX4H73FW
Further company coverage: BTCY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biotricity
See all newsBrief: Biotricity Accelerated Timeline To Achieving EBITDA Positive
Biotricity Inc reports results for the quarter ended in March - Earnings Summary
Biotricity Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Biotricity Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing
Biotricity Inc reports results for the quarter ended in December - Earnings Summary